Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2/3 1Phase 2 1

Status

Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 3FED 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 3Prostate Adenocarcinoma 1Neoplasm Metastasis 1

Interventions

Specimen Handling 641pembrolizumab 585Magnetic Resonance Spectroscopy 555Carboplatin 431Cyclophosphamide 381Cisplatin 379Biopsy 376Nivolumab 315Paclitaxel 314Gemcitabine 308Radiotherapy 286Bevacizumab 235Dexamethasone 218fludarabine 206Docetaxel 194durvalumab 189Oxaliplatin 189venetoclax 187Rituximab 175Fluorouracil 175atezolizumab 172Pemetrexed 167Capecitabine 164Radiosurgery 162Doxorubicin 162Radiation 160Ipilimumab 146Lenalidomide 140Leucovorin 138Etoposide 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
histrelin × 90 days × Clear all
NCT04513717 2026-05-04

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

NRG Oncology

Phase 3 Active not recruiting
2,753 enrolled
Genitourinary

Prostatic Neoplasms

NCT05050084 2026-05-04

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NRG Oncology

Phase 3 Active not recruiting
2,050 enrolled
Genitourinary

Prostate Adenocarcinoma

NCT06378866 2026-04-20

DIVINE

Mayo Clinic

Phase 2 Recruiting
532 enrolled
Genitourinary

Prostatic Neoplasms

NCT04787744 2026-04-08

VA STARPORT

VA Office of Research and Development

Phase 2/3 Recruiting
464 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡